Valuation: Ipca Laboratories Limited

Market Cap 447B 4.64B 4.08B 3.79B 3.48B 6.54B 6.64B 45.04B 17.6B 220B 17.43B 17.06B 760B P/E 2027 *
32.1x
P/E 2028 * 26.9x
Enterprise Value 435B 4.52B 3.97B 3.69B 3.39B 6.37B 6.47B 43.85B 17.13B 214B 16.97B 16.61B 740B EV / Sales 2027 *
4.04x
EV / Sales 2028 * 3.53x
Free-Float
54.92%
Yield 2027 *
0.33%
Yield 2028 * 0.36%
1 day-0.47%
1 week-6.80%
Current month+3.55%
1 month+8.58%
3 months+15.74%
6 months+20.48%
Current year+23.78%
1 week 1,730.25
Extreme 1730.25
1,938.05
1 month 1,605.35
Extreme 1605.35
1,941.4
Current year 1,392
Extreme 1392
1,941.4
1 year 1,252.95
Extreme 1252.95
1,941.4
3 years 790.55
Extreme 790.55
1,941.4
5 years 670
Extreme 670
1,941.4
10 years 200
Extreme 200
1,941.4
Manager TitleAgeSince
Chief Executive Officer 53 2023-03-31
Chief Executive Officer 70 2023-03-31
Chief Tech/Sci/R&D Officer 52 2023-10-15
Director TitleAgeSince
Chairman 79 2012-07-04
Director/Board Member 79 2011-07-27
Director/Board Member 53 2008-11-10
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%-6.80% - - 4.64B
+0.86%+1.43%+48.50%+160.39% 1,057B
+1.59%+4.09%+55.34%+53.96% 624B
+0.95%+1.91%+35.91%+81.14% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.60%+2.95%+36.28%+39.04% 297B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+2.66%+21.87%+59.73% 201B
-1.18%-3.70%+14.23%+66.51% 162B
Average +0.38%+0.77%+26.57%+51.73% 401.55B
Weighted average by Cap. +0.71%+1.57%+36.19%+77.48%

Financials

2027 *2028 *
Net sales 108B 1.12B 982M 913M 838M 1.57B 1.6B 10.85B 4.24B 52.94B 4.2B 4.11B 183B 120B 1.25B 1.1B 1.02B 935M 1.76B 1.78B 12.09B 4.72B 59.03B 4.68B 4.58B 204B
Net income 14B 145M 128M 119M 109M 205M 208M 1.41B 551M 6.88B 546M 534M 23.8B 16.7B 173M 152M 142M 130M 244M 248M 1.68B 657M 8.21B 651M 637M 28.38B
Net Debt -11.82B -123M -108M -100M -92.03M -173M -176M -1.19B -465M -5.81B -461M -451M -20.1B -23.66B -246M -216M -201M -184M -346M -351M -2.38B -931M -11.63B -922M -902M -40.22B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
17,210
Date Price Change Volume
26-07-24 1,762.70 -0.47% 2,343
26-07-23 ₹1,771.10 -0.93% 3,041
26-07-22 ₹1,787.65 -0.62% 6,888
26-07-21 ₹1,798.80 -1.77% 7,736
26-07-20 ₹1,831.30 -3.86% 18,462
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,762.70INR
Average target price
1,733.50INR
Spread / Average Target
-1.66%

Quarterly revenue - Rate of surprise